Messenger RNA (mRNA) vaccines have undoubtedly transformed public health, especially highlighted by their rapid deployment during the COVID-19 pandemic. However, their variable efficacy among individuals and the need for frequent updates to counter viral mutations have exposed critical vulnerabilities. Manufacturing complexities, stringent cold chain requirements, and unpredictable dosing within lipid nanoparticle delivery vehicles have also underscored the necessity for complementary strategies. The DNA origami-based DoriVac seeks to address these challenges by enabling unparalleled control over vaccine composition at the nanoscale, ensuring precise spatial arrangement of immune-stimulating elements and antigens.

At the heart of DoriVac’s technology lies DNA origami, a technique that engineers DNA to fold into highly defined three-dimensional nanostructures. These square block-shaped constructs serve a dual purpose: one face displays immune-activating adjuvant molecules, while the opposing side presents pathogen-specific antigens. This spatially controlled display is critical; by tuning the nanometer-scale distances between adjuvant molecules, researchers optimize the activation of dendritic cells, the immune system’s sentinel antigen-presenting cells. Enhanced dendritic cell activation cascades into a more vigorous and diverse mobilization of humoral and cellular immunity, including potent B cell antibody production and activation of CD4+ and CD8+ T cell subsets essential for viral clearance and long-term protection.

The Wyss Institute team deployed the DoriVac platform to develop vaccines that incorporate the HR2 peptide, a conserved region found in the spike proteins of diverse viruses such as SARS-CoV-2, HIV, and Ebola. These vaccines elicited compelling immune responses in murine models, significantly surpassing those generated by free antigens and adjuvants administered without the nanostructured framework. Notably, the SARS-CoV-2 HR2-targeting DoriVac induced a broad spectrum of immune cells, encompassing activated dendritic cells, memory T cells proficient in cytotoxic functions, and antibody-secreting plasma cells, all key players in sustained antiviral immunity.

Transitioning from animal studies to human systems, researchers employed an advanced human lymph node-on-a-chip platform to simulate and assess how DoriVac would perform in a human immune context. This microfluidic technology provides a dynamic and controllable environment that closely mimics the physiology of human lymphoid tissue, where initial immune activation occurs. Here, the SARS-CoV-2 HR2 DoriVac vaccine profoundly stimulated dendritic cells to secrete inflammatory cytokines and expanded populations of functional CD4+ and CD8+ T cells. Such results underscore the considerable translational potential of DoriVac vaccines and support their progression toward clinical evaluation.

Perhaps most strikingly, direct comparisons between DoriVac vaccines presenting the full SARS-CoV-2 spike protein and commercially available mRNA vaccines from Moderna and Pfizer/BioNTech revealed that DoriVac could elicit comparable levels of T cell and B cell responses. This parity was observed in preclinical mouse models receiving booster doses—a gold standard in assessing vaccine efficacy. The implications extend beyond immune activation; the structural stability of DoriVac vaccines circumvents the necessity for ultracold storage that hampers mRNA vaccine distribution, particularly in resource-constrained settings. Moreover, the relatively straightforward manufacturing process promises scalability and cost-effectiveness, factors critical for global vaccine accessibility.

The molecular precision of DoriVac offers significant advantages in safety and customization. By programming immune recognition mechanisms at the nanoscale, it minimizes off-target effects commonly associated with lipid nanoparticle-based delivery systems. Additionally, the self-adjuvanted nature of the DNA origami vaccine enhances immune stimulation without requiring separate adjuvant components. Early studies indicate a favorable safety profile, further substantiating the platform’s suitability for diverse clinical applications.

DoriVac’s creation is the culmination of interdisciplinary collaboration integrating expertise from structural DNA nanotechnology, immunology, microengineering, and virology. Led by Professor William Shih and Dr. Yang (Claire) Zeng, the initiative represents a fusion of fundamental science and translational vision. Zeng’s leadership in advancing DoriVac encompassed initial cancer immunotherapy applications, which serendipitously dovetailed with infectious disease needs amidst the ongoing pandemic. The coupling of DNA origami with organ-on-chip technologies, engineered by Dr. Donald Ingber’s team, exemplifies this synergy, producing predictive human immune models conducive to accelerating vaccine development cycles.

As the scientific community anticipates the next generation of vaccines with enhanced efficacy, durability, and accessibility, platforms like DoriVac may form the cornerstone of future pandemic preparedness. Their modularity permits rapid reprogramming to address emerging pathogens, while their robust immune activation profiles enhance both the magnitude and breadth of protective responses. This novel approach not only augments our arsenal against known viral threats but also charts a sophisticated path to anticipate and mitigate future infectious disease challenges.

With promising preclinical data validating the feasibility and superiority of DoriVac, the research consortium is poised to advance toward clinical trials. Commercialization efforts led by DoriNano, co-founded by Dr. Zeng, aim to translate this innovation from laboratory benches to global healthcare systems. Their success could redefine vaccine paradigms, merging the blueprint of life, DNA, with cutting-edge immunoengineering, to deliver vaccines that are smarter, safer, and more widely available.

In sum, DoriVac represents an exciting convergence of nanotechnology and immunotherapy, encapsulating the potential to revolutionize vaccine science. By delivering a potent cocktail of vaccine and adjuvant with nanometer precision, this platform amplifies immune responses beyond current capabilities. Its stability and manufacturability hold promise for equitable distribution worldwide, breaking down barriers imposed by cold chains and supply complexities. As infectious diseases continue to challenge humanity, such innovations may well be our most formidable defense.

Subject of Research: Animals

Article Title: DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases

Web References:

• Wyss Institute Technology: DoriVac Information
• Wyss Institute at Harvard University: https://wyss.harvard.edu

Image Credits: Wyss Institute at Harvard University

Keywords: DNA origami, vaccine development, infectious diseases, immunology, adjuvants, dendritic cells, antigen presentation, humoral immunity, cellular immunity, SARS-CoV-2, mRNA vaccines, nanotechnology

Protein nanoparticles have long been recognized for their capacity to enhance immune responses by displaying multiple copies of antigens in periodic arrays that mimic the spatial arrangement of epitopes on actual pathogens. However, conventional nanoparticle platforms frequently rely on carriers derived from organisms unrelated to the target pathogen, which introduces risks of unwanted immune interference or suboptimal antigen presentation. Moreover, pre-existing immunity against the nanoparticle scaffold and concerns over potential autoimmunity prompted by conserved epitopes have restricted their widespread application.

Addressing this considerable challenge, the team engineered P. falciparum PLP synthase, a multisubunit enzyme complex with no known human ortholog, to serve as a self-derived nanoparticle scaffold. This innovation uniquely minimizes the risks of autoimmune reactions and pre-existing immunity. By fusing it genetically with two key Plasmodium antigens—the P. falciparum circumsporozoite protein (CSP), which plays a critical role during liver infection, and the Plasmodium vivax cell-traversal protein for ookinetes and sporozoites (CelTOS), essential for host cell penetration—the engineered nanoparticles induce robust, dual-specific antibody responses targeting different stages of the malaria parasite’s life cycle.

Detailed immunization studies showed that mice receiving three doses of this multivalent vaccine exhibited exceptionally high titers of antibodies against both CSP and CelTOS antigens. Most remarkably, these immunized mice experienced complete sterile protection when challenged with infectious Plasmodium sporozoites, a gold standard outcome in malaria vaccine development indicating elimination of the parasite before establishment of infection.

To reveal the structural basis underlying nanoparticle stability and antigen presentation, researchers utilized cutting-edge cryogenic electron microscopy (cryo-EM), resolving the PLP nanoparticle at an extraordinary resolution of 2.95 angstroms. This atomic-level structural insight allowed the identification and rational engineering of amino acid substitutions that enhanced the nanoparticle’s stability, ensuring consistent and scalable manufacturing feasibility without compromising antigen display or immunogenicity.

The vaccine platform’s intrinsic advantages stem not only from its parasite origin but also from its modular nature. Unlike carriers derived from bacterial or viral sources, the Plasmodium PLP synthase scaffold lacks sequence homology with human proteins, substantially reducing the risk of eliciting autoreactive immune responses. Furthermore, since the platform components are native to the same species as the targeted pathogen, this self-derivation facilitates more physiologically relevant antigen presentation, maximizing the quality of antibody binding and immune activation.

Additional evaluation of the particle’s biophysical properties confirmed favorable manufacturing parameters, such as thermal stability and structural integrity under formulation and storage conditions. This presents a compelling advantage over existing nanoparticle vaccines that often require complex stabilization strategies or cold chain logistics, thereby limiting their deployment in resource-limited endemic regions where malaria burden is highest.

From a translational perspective, this discovery opens a versatile avenue for multivalent infectious disease vaccine design. The principles demonstrated—deploying pathogen-derived enzymatic nanoparticles combined with structurally rational antigen engineering—could be adapted to other challenging pathogens requiring complex immunity, ranging from other parasitic diseases to emerging viruses.

The multivalent vaccine’s ability to target antigens from two distinct Plasmodium species further represents a significant leap beyond monovalent immunogens. Achieving cross-species protection could substantially curtail malaria transmission cycles, particularly in regions co-endemic for both P. falciparum and P. vivax, the two most widespread human malaria parasites.

In summary, this pioneering work disrupts conventional vaccine design paradigms by integrating molecular engineering, structural biology, and immunology innovations to create a malaria vaccine candidate with unprecedented levels of protection demonstrated preclinically. These findings propel Plasmodium PLP synthase nanoparticles to the forefront of next-generation vaccine platforms capable of eliciting sterile immunity, a long-sought goal in combating malaria’s global toll.

Looking towards clinical application, further studies in non-human primates and eventual human trials will be crucial to confirm safety, immunogenicity, and protective efficacy in diverse populations. The simplicity and potency of this malaria vaccine candidate raise hopes for addressing persistent vaccine challenges against parasitic infections and beyond.

This work exemplifies the power of leveraging pathogen biology itself to craft better vaccines, transforming inherent parasite molecules into powerful immunological tools. Such innovations offer promising strategies not only to end malaria but also to revolutionize vaccine development against a broad array of infectious diseases demanding next-level solutions.

As the global health community continues striving for durable malaria control and elimination, the introduction of PLP synthase-based nanoparticles heralds a new chapter where engineered biological systems from the pathogen can be turned against it to achieve sterile, vaccine-mediated immunity with far-reaching public health impact.

Subject of Research: Development of a Plasmodium falciparum-derived nanoparticle vaccine platform for multivalent malaria immunization.

Article Title: A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.

Article References:
Shi, D., Ma, R., Gupta, R. et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02209-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41564-025-02209-y